BenzingaOctober 20, 2026 at 5:55 AM NY7 Days Ago
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
